ClinicalTrials.Veeva

Menu

Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women

L

Laboratorios Andromaco

Status and phase

Completed
Phase 1

Conditions

Contraception
Bleeding Pattern

Treatments

Drug: Meloxicam 2.4 g
Drug: Meloxicam 3.0 g

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01839643
AVM-01001

Details and patient eligibility

About

In this study, the investigators propose to assess if a non-hormonal agent is absorbed by a local route (vaginal) and to observe the effect on follicular development.

Full description

Each volunteer will participate for 3 menstrual cycles, beginning with one menstrual control cycle without treatment, following by one menstrual cycle with meloxicam ring administration, and finishing with another control menstrual cycle.

Meloxicam will be administered in the second menstrual cycle via a vaginal ring in two doses of 2.4 g or 3.0 g/ring. The safety of the vaginal ring and the absorption of meloxicam will be assessed. Also the effect on follicular development and if it maintains ovarian cyclicity, as shown in a recent study with oral administration, will be assessed.

Enrollment

13 patients

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Previous (or history of) proven fertility
  • Regular menstrual cycle
  • Surgically sterile
  • Without breastfeeding
  • Haemoglobin at least 11g/dL
  • Willing to participate in the study

Exclusion criteria

  • Allergy to meloxicam or other NSAID
  • Allergy to silicone polymer
  • Vaginal discharge non diagnosticated
  • History of shock toxic syndrome
  • History of : gastrointestinal, bleeding, renal, liver, heart, brain,clot, endocrine or pulmonary disorders

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

13 participants in 2 patient groups

2.4 g Meloxicam Vaginal Ring
Experimental group
Description:
Continuous wearing during one menstrual cycle (6 participants)
Treatment:
Drug: Meloxicam 2.4 g
3.0 g Meloxicam Vaginal Ring
Experimental group
Description:
Continuous wearing during one menstrual cycle (6 participants)
Treatment:
Drug: Meloxicam 3.0 g

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems